• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1274345 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type( ~- M" ]6 z  G0 J
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
5 Q& c! b" ]) _% j7 N2 o$ E+ Author Affiliations
" f# }2 E% |. z! n* U/ q' g! [* a2 C6 G% F1 D( `9 S$ E
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
* z' I3 I& c) \; e) X, V) B2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; U' |, S: D; ]; d' K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " Y! _$ w  v/ \" c+ g% h! J( i0 G7 s
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan , \5 y; f; A) X+ b  t/ z, t; ]
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 0 w: w6 X% B3 X* K* Z
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 L: C$ ?0 d3 ^) D' W4 v7Kinki University School of Medicine, Osaka 589-8511, Japan * V3 ~! S4 r8 Q6 f* w$ h% m
8Izumi Municipal Hospital, Osaka 594-0071, Japan ! t  h  B9 x. X8 G4 ~4 F
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan + K! q. G" ?+ N! k% A% v
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp : G7 S5 u# e3 e0 R
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 2 S3 a* Z. Q0 H$ W7 @7 Z3 b

) z* {4 y" i( m' u
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 8 e  m) g" q* D+ c9 j" |, j6 ^

7 {! N1 F3 a# l5 ^9 ~' E( aAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
& Q) y8 w+ J+ E4 o' L' `, g  h2 \2 K( N
' n' M. F6 v4 x/ s! Q( \4 NAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  - O/ B: ?# p. `1 |( M/ e

0 w, D, z0 D/ x; z" N6 X2 lPublished online on: Thursday, December 1, 2011
# c2 `7 ^  @& i6 ?3 O: F( c
8 Q3 a/ ^; [1 BDoi: 10.3892/ol.2011.507
9 f% N1 D, H( O+ W3 D9 E% i& R
; J2 d& q, _$ L& qPages: 405-410 6 N) l2 e; Q- v' ~5 M& c4 u5 G
& x5 z7 `# J$ H: d+ V1 M9 c2 f
Abstract:% q' l0 X4 b) P& N/ q, K  Q
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
, P; q% ?+ E# j0 u2 t6 b7 X) y
6 t3 L( h) P( u% N1 {! g. i6 |
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population; P3 Z& U+ h1 o( J+ {" K: x1 e" R
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3   l! J% w8 u' C) W' d+ H
+ Author Affiliations" e5 f- y/ i6 V! G' Y
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu / ^4 A+ f1 |, l1 ~3 L
2Department of Thoracic Surgery, Kyoto University, Kyoto . }3 P$ T4 p) x3 X3 x
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan . Z: E( }4 D0 v, M' A4 [
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp $ {8 L2 N. O9 Y1 }
Received September 3, 2010. 3 E& m; j  r8 y: D! }
Revision received November 11, 2010.
+ V! j4 \: M+ y4 s) ]Accepted November 17, 2010. ' T6 e( f+ q" h8 q! }1 P) J$ c
Abstract' m8 T4 w7 c  d+ H% o% G
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
) \% T1 T+ h9 cPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
6 |0 T0 }% \6 g8 a1 t0 v/ EResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. . P/ t3 ~  P* U- ~2 L  a0 e6 T" y
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ; K, I& O0 e1 Q0 }
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。, g" J3 g6 v9 j! _2 Q
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?% t8 F3 T) [' z8 ~
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy0 a$ _  W  _0 o7 |
http://clinicaltrials.gov/ct2/show/NCT01523587/ ?# r- x' k; B& q. W: Q- B6 l- Q

" }7 F4 ?# @2 Y8 E) r( Z* hBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
8 d; V- ]: t. d  Ihttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
. P8 j- k3 E$ G7 F) e
; _% P8 x/ L  m0 Q# x从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。, p/ ^$ P* I" T3 E5 ]- {) b2 p
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 . A: r; v, W$ ~+ e" S5 A# h
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。" p/ L5 m; G. e% _. F! _# N4 M
至今为止,未出 ...

6 K* o. N2 H6 n% I5 S" q没有副作用是第一追求,效果显著是第二追求。
1 I+ L6 Q( E8 r; \5 y: W* I  u& H不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表